{
  "company": {
    "name": "Endocyte",
    "website": "https://endocyte.com/",
    "record": "https://startuphistory.org/c/endocyte.com"
  },
  "status": null,
  "history_since": "2008-01-04T01:05:24.000Z",
  "baseline": {
    "snapshot_id": "021b950a9d05da1e454592826d4874ca3f88a1df2e4c13b9c89c7361cb62e906",
    "observed_at": "2015-06-04T16:40:18.000Z",
    "headline": "The future of precision medicine",
    "description": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
    "evidence": "https://web.archive.org/web/20150604164018/http://endocyte.com/",
    "evidence_kind": "internet_archive",
    "facts": null,
    "basis": "first_observation",
    "is_change": false
  },
  "live_captures": 1,
  "last_checked": "2026-11-05T13:54:01.659Z",
  "live_status": null,
  "messaging": [
    {
      "quote_observed_at": "2017-07-09T16:51:41.000Z",
      "variants": [
        {
          "headline": "The future of precision medicine",
          "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
          "observed_at": "2015-06-04T16:40:18.000Z",
          "evidence": "https://web.archive.org/web/20150604164018/http://endocyte.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "The future of precision medicine",
          "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
          "observed_at": "2016-10-02T00:51:21.000Z",
          "evidence": "https://web.archive.org/web/20161002005121/http://endocyte.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "The future of precision medicine",
          "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
          "observed_at": "2017-07-09T16:51:41.000Z",
          "evidence": "https://web.archive.org/web/20170709165141/http://endocyte.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "The future of precision medicine",
      "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
      "from": "2015-06-04T16:40:18.000Z",
      "to": "2017-07-09T16:51:41.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20170709165141/http://endocyte.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2015-06-04T16:40:18.000Z",
          "to": "2017-07-09T16:51:41.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2019-09-17T11:54:31.000Z",
      "variants": [
        {
          "headline": "Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)",
          "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
          "observed_at": "2018-07-01T06:15:46.000Z",
          "evidence": "https://web.archive.org/web/20180701061546/https://endocyte.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)",
          "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
          "observed_at": "2019-08-18T09:46:38.000Z",
          "evidence": "https://web.archive.org/web/20190818094638/https://endocyte.com/",
          "evidence_kind": "internet_archive"
        },
        {
          "headline": "Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)",
          "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
          "observed_at": "2019-09-17T11:54:31.000Z",
          "evidence": "https://web.archive.org/web/20190917115431/https://endocyte.com/",
          "evidence_kind": "internet_archive"
        }
      ],
      "headline": "Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)",
      "subhead": "Endocyte seeks to find new treatments for cancer that pair companion imaging agents with small molecule drug conjugates (SMDCs).",
      "from": "2018-07-01T06:15:46.000Z",
      "to": "2019-09-17T11:54:31.000Z",
      "captures": 3,
      "evidence": "https://web.archive.org/web/20190917115431/https://endocyte.com/",
      "evidence_kind": "internet_archive",
      "seen": {
        "between": {
          "from": "2018-07-01T06:15:46.000Z",
          "to": "2019-09-17T11:54:31.000Z"
        }
      },
      "current": false
    },
    {
      "quote_observed_at": "2026-11-05T13:54:01.659Z",
      "variants": [
        {
          "headline": "Reimagining medicine, together.",
          "subhead": "For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic",
          "observed_at": "2026-11-05T13:54:01.659Z",
          "evidence": "https://www.novartis.com/",
          "evidence_kind": "live_capture"
        }
      ],
      "headline": "Reimagining medicine, together.",
      "subhead": "For more than 250 years–and 30 years as Novartis–we’ve pursued scientific breakthroughs for one purpose: people. Today, we take on the toughest challenges in healthcare and turn innovations into medic",
      "from": "2026-11-05T13:54:01.659Z",
      "to": "2026-11-05T13:54:01.659Z",
      "captures": 1,
      "evidence": "https://www.novartis.com/",
      "evidence_kind": "live_capture",
      "seen": {
        "on": "2026-11-05T13:54:01.659Z"
      },
      "current": true
    }
  ],
  "changes": [
    {
      "n": 1,
      "id": "page-12a45fe40292981b8e800b222552ee3887118d51d4565bdc74a7d5a8011309d3:021b950a9d05da1e454592826d4874ca3f88a1df2e4c13b9c89c7361cb62e906:hiring:20dd4c09cc4ab0aa",
      "before_evidence": "https://web.archive.org/web/20130725024301/http://www.endocyte.com:80/",
      "before_evidence_kind": "internet_archive",
      "kind": "hiring",
      "label": "Hiring",
      "summary": "Added a careers page.",
      "between": {
        "from": "2013-07-25T02:43:01.000Z",
        "to": "2015-06-04T16:40:18.000Z"
      },
      "evidence": "https://web.archive.org/web/20150604164018/http://endocyte.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": "https://startuphistory.org/t/added-careers-page"
    },
    {
      "n": 2,
      "id": "page-4f6eff009d608d323a40ee9d04c6f956f71efd134671e691932dc9eff8bb2ebe:8e741dd9b00cddc65c981c8cd1371776611095745d0d94b69a38a2ebb6876050:headline:dc4308708275520c",
      "before_evidence": "https://web.archive.org/web/20170709165141/http://endocyte.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “The future of precision medicine” to “Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)”.",
      "between": {
        "from": "2017-07-09T16:51:41.000Z",
        "to": "2018-07-01T06:15:46.000Z"
      },
      "evidence": "https://web.archive.org/web/20180701061546/https://endocyte.com/",
      "evidence_kind": "internet_archive",
      "basis": "page_facts",
      "topic": null
    },
    {
      "n": 3,
      "id": "page-6e815a13b1ed0fa4ee7097a2cd70b0481ad17e82d4261b01c40873a4b401270b:b682c610e6ff8f890c602c777711a23e3fa923f5222824725fd8f7f20bf73d9e:headline:d2f44a540791f2b6",
      "before_evidence": "https://web.archive.org/web/20190917115431/https://endocyte.com/",
      "before_evidence_kind": "internet_archive",
      "kind": "headline",
      "label": "Headline",
      "summary": "Changed its homepage headline from “Endocyte announces Global Phase 3 VISION study of 177 Lu-PSMA-617 in metastatic castration-resistant prostate cancer (mCRPC)” to “Reimagining medicine, together.”.",
      "between": {
        "from": "2019-09-17T11:54:31.000Z",
        "to": "2026-11-05T13:54:01.659Z"
      },
      "evidence": "https://www.novartis.com/",
      "evidence_kind": "live_capture",
      "basis": "page_facts",
      "topic": null
    }
  ],
  "update": null,
  "method": {
    "version": "messaging-v1",
    "description": "https://startuphistory.org/method"
  },
  "license": "CC-BY-4.0",
  "cite": "StartupHistory, “Endocyte” company record, https://startuphistory.org/c/endocyte.com"
}